BrainParrot

What does the WHO report say about India’s TB target?

GS2Full notePublished:

Source: The Hindu, 20 November 2026

Summary

  • WHO's Global Tuberculosis Report, released on 12 November 2026, estimates that 10.6 million people developed TB worldwide in 2025. India accounts for nearly a quarter of the world's burden and has missed its own target of eliminating TB by 2025.
  • India's TB mortality fell 38% from 2015 to 2025, and it notified 25.3 lakh cases in 2025. WHO has not published India's 2025 incidence because new district-level surveillance data are under review, with an update expected in early 2027.

UPSC relevance: GS2 Health / GS3 S&T (health) – TB elimination, surveillance

Key facts for Prelims

  • WHO Global TB Report 2026: released 12 Nov 2026, annual flagship report; assesses TB against the End TB Strategy.
  • National Strategic Plan for TB Elimination 2017–2025 targets: 80% cut in incidence and 90% cut in mortality (2015 baseline), and no family facing catastrophic costs.
  • India's 2025 elimination target was five years ahead of the SDG deadline of 2030.
  • WHO End TB global 2025 targets: 50% incidence and 75% mortality reduction (vs 2015).
  • RNTCP was renamed NTEP in 2020.
  • NTEP strategic pillars: Detect – Treat – Prevent – Build.
  • PMTBMBA: launched 9 Sept 2022.
  • Ni-kshay Poshan Yojana: DBT nutrition support, started April 2018. The Ni-kshay portal is the web-based patient management and surveillance system.
  • Definitions: incidence = new cases in a period; prevalence = existing cases at a point or period; notifications = diagnosed and reported cases.
  • BPaLM: six-month all-oral regimen for eligible patients with multidrug- or rifampicin-resistant TB.
  • TB Mukt Bharat Abhiyaan is the vehicle for active case-finding and rapid molecular tests.
  • The 2020–21 national TB prevalence survey is the reference against which the new surveillance data are being compared.
  • CBNAAT and Truenat are the molecular diagnostic platforms expanded in India.

Data and details

  • Global: 10.6 million people developed TB in 2025. India is about a quarter of global burden.
  • India's TB mortality fell 38%, from 28 deaths per lakh in 2015 to 18 per lakh in 2025.
  • The article notes this exceeded the WHO 2020 milestone of 35%, but five years late.
  • The 2025 target was a 75% reduction, and the national target is 3 per lakh.
  • The NSP baseline for mortality was 32 per lakh, to be cut 90% to three.
  • India diagnosed and notified 25.3 lakh cases in 2025.
  • NSP incidence goal: from 217 per lakh (2015) to 43 per lakh (2025), an 80% reduction.
  • WHO's 2025 report (as cited): incidence fell from 237 per lakh (2015) to 187 per lakh (2024), about 21%. The article says this is well short of the national plan, and WHO's revised baseline (237) and the NSP baseline (217) should not be treated as one series.
  • India's 2025 incidence has not been published, so the latest change in burden cannot yet be assessed. This does not mean India lacked TB data for 2025.
  • Rapid diagnostic tests as the initial test: 46% of diagnosed cases in 2025, up from 38% in 2024.
  • Surveillance exercise: population-level surveillance in 50 representative districts. The first round was completed in 2025.
  • The findings are being examined alongside the 2020–21 national prevalence survey, and their comparability must be assessed first.
  • The updated estimate is expected in early 2027.
  • Drivers of the gap (article): undiagnosed or delayed diagnosis, uneven access in remote areas and vulnerable groups, private-sector notification and continuity issues, undernutrition, crowded housing, poor ventilation, patient costs (travel, tests, nutrition, lost wages) even though medicines are free, and drug-resistant TB.
  • The article lists screening and then confirmatory diagnosis and treatment linkage as the weak link.

Static–dynamic linkage

  • Health indicators are measured against international frameworks. India's target of 2025 was five years ahead of the SDG deadline of 2030, set in the National Strategic Plan (NSP) 2017–2025.
  • Concepts the news illustrates:
    • Incidence is new cases in a period. Prevalence is people with the disease at a point in time or within a period. Notifications are cases diagnosed and reported to the health system.
    • The gap between estimated incidence and notifications shows diagnosis/reporting gaps, but is not an exact count of the undiagnosed.
    • Disease-burden figures are modelled estimates, and rely on surveys and surveillance.
  • Social determinants of health: undernutrition, crowded housing and poor ventilation, out-of-pocket costs, and the private-sector care pathway. TB is therefore a development and governance issue, not just a medical one.

Syllabus mapping: GS2 – Governance: Health, welfare schemes and their performance | GS3 – S&T: Health technology (rapid molecular diagnostics, drug-resistant TB regimens) | GS2 – IR: International organisations (WHO), SDG commitments

Background primer

WHO Global Tuberculosis Report

What it is:
An annual flagship WHO publication assessing the global TB epidemic. It evaluates countries against the End TB Strategy.

National Strategic Plan (NSP) for TB Elimination 2017–2025 / NTEP

What it is:
India's plan for ending TB. It was approved by the Health Minister on 8 May 2017 and has operated nationwide since then.
Mandate:
80% fall in incidence and 90% fall in deaths (from a 2015 baseline), and zero catastrophic expenditure due to TB.
Why it matters:
move from TB control to elimination through early diagnosis, complete treatment, prevention and social support.

Pradhan Mantri TB Mukt Bharat Abhiyaan (PMTBMBA) and Ni-kshay Poshan Yojana (NPY)

What it is:
PMTBMBA is a component of NTEP. It was launched on 9 September 2022 to provide extra support to TB patients, deepen community involvement and use CSR.
Why it matters:
undernutrition is a major TB risk factor, so nutrition support is built into treatment.

WHO End TB Strategy (as stated in the article)

Additional context

  • The Health Ministry reports a 38% fall in India's TB mortality since 2015, against a global decline of 35%, and a 94% treatment success rate for drug-susceptible TB.
  • The government says 96% of the programme's funding is met from domestic resources.
  • WHO drew on the Registrar General's Sample Registration System, verbal autopsy studies and Ni-kshay programme data to strengthen mortality estimates.
  • WHO's method for India's incidence uses a country-specific dynamic model calibrated to the national prevalence survey and other data such as notifications and drug sales.
  • The WHO report itself footnotes that estimates of TB incidence in India are under review.
  • WHO reports India accounted for 26% of global TB deaths among HIV-negative people in 2025.
  • Four high-burden countries outside the African and European regions reached the 35% milestone (Bangladesh, China, India, Viet Nam); China and India did so in 2025.
  • India's notified cases were 26.18 lakh in 2024, against 25.3 lakh in 2025.

Mains dimensions

  • Mortality success vs incidence uncertainty: Deaths fell 38%, beating the WHO 2020 milestone but five years late, and are far above India's own target of 3 per lakh. WHO has withheld the 2025 incidence figure, so the shortfall cannot be measured.
  • Data and surveillance governance:
  • Estimates depend on models and on survey comparability, as the 50-district sentinel data are being reconciled with the 2020–21 prevalence survey.
  • Baselines differ (217 NSP vs 237 WHO), so progress claims need care.
  • Notifications are not incidence. Reliable estimates affect planning and credibility.
  • Diagnosis-to-treatment cascade:
  • Rapid tests rose from 38% to 46% of initial diagnoses.
  • Screening must lead to confirmation and treatment.
  • Access is uneven, and much care is in the private sector, making notification and continuity of treatment harder.
  • Social determinants: Undernutrition raises the risk of active TB. Crowding and poor ventilation aid transmission. Treatment-related costs cause catastrophic expenditure even with free drugs, which is itself an NSP target. This links to nutrition (NPY) and social-protection policy.
  • Drug-resistant TB: Resistance complicates treatment. Shorter all-oral regimens such as six-month BPaLM reduce the burden, but identifying resistance and linking patients to care remain challenges.
  • Way forward: Close diagnostic and treatment gaps, bring the private sector fully into notification and continuity, expand nutrition and financial support, and publish transparent, comparable estimates after the 2027 revision.

Possible Mains question

**GS2 (Health/Governance), 15 marks:** "India has cut TB mortality sharply but missed its 2025 elimination target. Analyse the reasons for the shortfall and discuss the role of reliable surveillance data and social determinants in India's TB response."

Related topics

  • National TB Elimination Programme, Ni-kshay platform and the Nikshay Mitra/PMTBMBA initiatives
  • Sustainable Development Goal 3 (health) and the WHO End TB Strategy
  • Drug-resistant TB (MDR/RR-TB), BPaLM regimen, CBNAAT/Truenat diagnostics
  • Health surveillance: prevalence surveys, Sample Registration System, sentinel surveillance
  • Nutrition and social protection: DBT schemes, catastrophic health expenditure, role of the private health sector

Topics: GS2Sci & Tech

How we write and check these notes →

All current affairs of 20 November 2026 → · UPSC Current Affairs